Sivak leaving post as HHS CTO

Bryan Sivak, chief technology officer at the Department of Health and Human Services (HHS), will leave his position in April.

HHS Secretary Sylvia M. Burwell announced Sivak's impending departure in an email to staff.

"Since joining us in 2012, Bryan has been a force for promoting innovation across the department, designing and deploying initiatives that improve the performance of the department for those we serve, and for our employees," HHS Secretary Sylvia Burwell wrote in a March 27 email to staff. "Bryan has championed some of the department’s most innovative projects."

Those projects include the development of a "Buyer's Club" to share institutional wisdom on procurement, and the ongoing administration of the Entrepreneurs in Residence program, which taps private sector developers to work inside HHS for a year on high-profile technology goals. Sivak also was a leader in the HHS IDEA Lab, which has empowered tech employees at the department to experiment with new ideas and collaborate with the private sector on data applications.

He joined HHS in June 2012, succeeding Todd Park, who became White House CTO.

Before starting in public service, Sivak founded InQuira, a Silicon Valley knowledge management and self-service software company, which was later acquired by Oracle. He served as chief innovation officer for the state of Maryland before joining HHS.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.